Department of Pharmaceutical Sciences
College of Pharmacy
University of Nebraska Medical Center
986025 Nebraska Medical Center
Omaha, NE 68198-6025
Dr. Ronning’s research foci are the discovery and development of novel anti-infective and anti-cancer compounds. The anti-infective drug discovery efforts are particularly interested on identifying and developing compounds possessing efficacy for treating Tuberculosis, but many targets are relevant to other bacterial pathogens. As a part of this discovery process, the research aims to understand the mechanistic details of protein function through structural characterization and enzyme kinetic studies, and to use that knowledge to identify inhibitors, assess mechanisms of inhibition, and detail the modes of interaction with the target protein. In addition, new cancer projects include understanding and targeting DNA repair mechanisms in Ovarian Cancer as well as lead optimization of compounds for treating Medulloblastoma.
Please visit the Ronning Group website for more information.
- Sudasinghe, T.D., Banco, M.T. & Ronning, D.R. Inhibitors of Mycobacterium tuberculosis EgtD target both substrate binding sites to limit hercynine production. Sci Rep 11, 22240 (2021).
- Si, A. et al. Stereoselective synthesis of a 4-a-glucoside of valienamine and its X-ray structure in complex with Streptomyces coelicolor GlgE1-V279S. Sci Rep 11, 13413 (2021).
- Khan, S.S., Sudasinghe, T.D., Landgraf, A.D., Ronning, D.R. & Sucheck, S.J. Total Synthesis of Tetrahydrolipstatin, Its Derivatives, and Evaluation of Their Ability to Potentiate Multiple Antibiotic Classes against Mycobacterium Species. ACS Infect Dis 7, 2876-2888 (2021).
- Alshammari, A.M. et al. Targeted Amino Acid Substitution Overcomes Scale-Up Challenges with the Human C5a-Derived Decapeptide Immunostimulant EP67. ACS Infect Dis 6, 1169-1181 (2020).